Clinical Trials
15 trialsNCT06784752 2026-04-30
NETTER-3
Novartis
Phase 3 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT00446082 2020-12-21
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Novartis
Phase 1 Completed
NCT01364415 2020-12-21
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Novartis
Phase 1 Completed
NCT01646684 2020-12-21
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
Novartis
Phase 1 Completed
NCT01915303 2020-09-18
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Novartis
Phase 2 Terminated
NCT02354508 2019-12-10
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis
Phase 3 Completed
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT01590199 2019-04-16
MACS2002
Novartis
Phase 1 Completed
NCT01137682 2018-04-05
PAOLA
Novartis
Phase 3 Completed
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT00690430 2013-07-30
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Novartis
Phase 3 Completed
NCT00088595 2012-06-04
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Novartis
Phase 2 Completed